<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01089361</url>
  </required_header>
  <id_info>
    <org_study_id>2009P000259</org_study_id>
    <nct_id>NCT01089361</nct_id>
  </id_info>
  <brief_title>Immunomodulatory Properties of Ketamine in Sepsis</brief_title>
  <official_title>Immunomodulatory Properties of Ketamine in Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess the effect of short-term infusion of ketamine at analgesic
      dosage on the immune response, morbidity and mortality among patients suffering from septic
      shock. We hypothesize that ketamine will modulate the cytokine response to sepsis and reduce
      morbidity and mortality.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Basic design A randomized placebo controlled trial of low dose ketamine in patients with
           severe sepsis in the ICU.

        2. Assembly of Subjects Patients meeting the ACCP/ SCCM definition of severe sepsis will be
           enrolled in the study5. These patients should have a known or suspected source of
           infection based on the clinical data at the time of screening. They must exhibit 3 or
           more of the following signs of clinical inflammation

             -  Core temperature &lt; 36ºC or &gt; 38ºC.

             -  Heart rate of 90 or greater not explained by another medical condition.

             -  A respiratory rate of &gt; 20 min-1, a PaCO2 &lt; 32min-1 or the need for mechanical
                ventilation.

             -  A white cell count of &lt; 4000 cell/ml or &gt; 12000 cells/ml or a WBC showing greater
                then 10% immature neutrophils.

           In addition the patient will have to be within 12 hours of the development of one or
           more organ dysfunctions as outlined in Bone et al 5.

           Several exclusion criteria will be in place to safeguard patient's safety 11. Patients
           with closed head trauma or with increased intracranial pressure will be excluded.
           Patients with a history of psychotic mental disease will also be excluded as they may be
           at risk for relapse following administration of ketamine.

        3. Exposures Patients will be randomized into a treatment group and a control group. The
           treatment group will receive 0.25mg/kg of ketamine over a period of one hour followed by
           a continuous infusion of ketamine at 0.1 mg/kg/hr for a further 23 hours. To help insure
           protocol compliance and safeguard patient care, a member of the study team will be
           present at the time the study drug infusion is started, and will also contact the
           clinical team when the infusion is due to be terminated. The dose of the ketamine is
           considered analgesic not anesthetic in nature and follows general practice in pain
           management 11. The control group will receive a similar volume of normal saline as a
           placebo. Additionally all patients enrolled in the study will receive lorazepam 1mg
           every 6 hours to further lower the risk of side effect from ketamine. Patients, staff
           and investigators will all be blinded to the treatment groups. All other care, including
           the need for further sedation, will be according to unit protocols.

           Prior to administration of the study drug a 10cc sample of the patient's blood will be
           drawn and frozen for later analysis. 2 hours after starting infusion another 10ml of
           blood will be obtained. Following 24 hour infusion of ketamine, blood samples will be
           drawn each day, for the following 7 days, processed and frozen.

           Patient demographic and clinical data will be collected on admission to the study and
           daily follow-up. Particular attention will be paid to calculation of the patient's
           APACHE II/MODS score on the day of admission and on the following days22. This will
           allow us to compare severity of disease in a potentially heterogeneous ICU patient
           population. We will also monitor use of the vasopressors, additional pain and sedative
           medication and physiological parameters (BP, HR, Sat, ABG, LFT, lactic acid) in studied
           population before and after administration of the drug. The adverse effect of ketamine
           will assessed by using delirium questionnaire and special chart designed to capture the
           emergence of side effect (delirium, psychosis, others).

        4. Outcomes and their measurement The primary outcome of the study will be serum levels of
           IL-6, IL-10 and TNFα and other cytokines over the first 7 days of admission. Measurement
           of cytokine levels will be done using enzyme linked immunoassay, or with flow cytometry
           at the end of the study by at researcher who will be blinded to the study groups. We
           also plan to separate leukocytes for further studies of mRNA levels to corroborate serum
           cytokine levels with activity of mRNA.

           Secondary outcomes will include adverse effects attributable to ketamine, organ
           failures, daily APACHE scores, length of ICU stay and 28 day mortality. A clinical
           research associate will carry out a daily patient assessment. This investigator will be
           blinded to the treatment groups. Data will be collected on a patient study chart. In
           addition to the incidence of organ dysfunction, death and length of stay, specific
           information will be gathered to assess patient's level of conscience, possible dreams or
           hallucinations and other effects, which may be attributable to ketamine.

        5. Substudy of serum samples We plan to perform real-time quantitative PCR analyses on the
           existing serum samples for the presence of bacterial and mitochondrial DNA on the
           samples. We will use primers targeting bacterial 16S-rRNA consensus areas and primers
           targeting gram-positive (S. Aureus), gram-negative (e. coli) and anaerobic (B. Fragilis)
           species. These tests may be able to accurately discriminate between systemic
           inflammation (&quot;SIRS&quot;) due to invasive bacterial infections from SIRS due to tissue
           injury than do conventional bacteriologic analyses.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Levels of IL-6, IL-10 and TNFα</measure>
    <time_frame>first 7 days of admission, Baseline and Day 7 reported</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Effects Attributable to Ketamine</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organ Failures</measure>
    <time_frame>7 days</time_frame>
    <description>Incidence of new organ failure as detected by Sequential Organ Failure Assessment [SOFA] score. Definitions are as follows. Central nervous system: delirium, coma, uncontrollable seizures, ICP&gt;20cm H2O Cardiac: MAP &lt;60mmHg, blood pressure supported with pressors, 50 &gt; HR &gt; 120 Respiratory: vented, RR&gt;30, PaO2&lt;60, PaCO2 &gt; 55, Sat&lt;92% Kidney: RIFLE criteria Anemia: Hct&lt;27, transfusion of PRBC Thrombocytopenia: platelet &lt; 50k, platelet transfusion Liver: biopsy, ALT&gt;200, AST&gt;200, t.bil&gt;2.0, ALP&gt;300 Coagulation failure: INR&gt;2 if no anticoagulation therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Physiology and Chronic Health Evaluation (APACHE) Scores</measure>
    <time_frame>First 24 hours after ICU admission</time_frame>
    <description>Difference in average APACHE-II score between the intervention and placebo groups. APACHE II (Acute Physiology and Chronic Health Evaluation II) is a severity of disease classification system for patients admitted to the Intensive Care Unit. It uses an integer score from 0 to 71 that is computed based on age, 12 routine physiological measurements (i.e. heart rate, temperature, laboratory values), and previous health status obtained during the first 24 hours after ICU admission. Higher scores correspond to more severe disease and a higher risk of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Intensive Care Unit (ICU) Stay</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28 Day Mortality</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>PCR Substudy</measure>
    <time_frame>Daily up to 7 days</time_frame>
    <description>PCR analysis on serum samples for presence of bacterial and mitochondrial DNA; This substudy was not done.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>Normal saline placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The control group will receive 0.25mg/kg of normal saline over a period of one hour followed by a continuous infusion of normal saline at 0.1 mg/kg/hr for a further 23 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The treatment group will receive 0.25mg/kg of ketamine over a period of one hour followed by a continuous infusion of ketamine at 0.1 mg/kg/hr for a further 23 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>The treatment group will receive 0.25mg/kg of ketamine over a period of one hour followed by a continuous infusion of ketamine at 0.1 mg/kg/hr for a further 23 hours.</description>
    <arm_group_label>Ketamine</arm_group_label>
    <other_name>Ketamine Hydrochloride</other_name>
    <other_name>Ketalar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline placebo</intervention_name>
    <description>The control group will receive 0.25mg/kg of normal saline over a period of one hour followed by a continuous infusion of normal saline at 0.1 mg/kg/hr for a further 23 hours.</description>
    <arm_group_label>Normal saline placebo</arm_group_label>
    <other_name>0.9% Sodium Chloride Solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients meeting the ACCP/ SCCM definition of severe sepsis will be enrolled in the
             study. These patients should have a known or suspected source of infection.

          -  Patients within 12 hours of the development of one or more organ dysfunctions

          -  Patients must exhibit 3 or more of the following signs of clinical inflammation:

               -  Core temperature &lt; 36ºC or &gt; 38ºC.

               -  Heart rate of 90 or greater not explained by another medical condition.

               -  A respiratory rate of &gt; 20 min-1, a PaCO2 &lt; 32min-1 or the need for mechanical
                  ventilation.

               -  A white blood cell count of &lt; 4000 cell/ml or &gt; 12000 cells/ml or a WBC showing
                  greater then 10% immature neutrophils.

        Exclusion Criteria:

          -  pregnant

          -  increased intracranial pressure or closed head injury

          -  history of psychotic mental disease

          -  receiving Continuous Veno - Venous Hemofiltration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Talmor, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Calandra T, Bochud PY, Heumann D. Cytokines in septic shock. Curr Clin Top Infect Dis. 2002;22:1-23. Review.</citation>
    <PMID>12520644</PMID>
  </reference>
  <reference>
    <citation>Laudanski K, Miller-Graziano C, Xiao W, Mindrinos MN, Richards DR, De A, Moldawer LL, Maier RV, Bankey P, Baker HV, Brownstein BH, Cobb JP, Calvano SE, Davis RW, Tompkins RG. Cell-specific expression and pathway analyses reveal alterations in trauma-related human T cell and monocyte pathways. Proc Natl Acad Sci U S A. 2006 Oct 17;103(42):15564-9. Epub 2006 Oct 10.</citation>
    <PMID>17032758</PMID>
  </reference>
  <reference>
    <citation>Kawasaki T, Ogata M, Kawasaki C, Ogata J, Inoue Y, Shigematsu A. Ketamine suppresses proinflammatory cytokine production in human whole blood in vitro. Anesth Analg. 1999 Sep;89(3):665-9.</citation>
    <PMID>10475301</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2010</study_first_submitted>
  <study_first_submitted_qc>March 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2010</study_first_posted>
  <results_first_submitted>December 22, 2015</results_first_submitted>
  <results_first_submitted_qc>July 21, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 21, 2017</results_first_posted>
  <last_update_submitted>July 21, 2017</last_update_submitted>
  <last_update_submitted_qc>July 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Daniel Talmor</investigator_full_name>
    <investigator_title>Professor of Anaesthesia</investigator_title>
  </responsible_party>
  <keyword>systemic inflammatory syndrome</keyword>
  <keyword>sepsis syndrome</keyword>
  <keyword>septic shock</keyword>
  <keyword>Cytokine</keyword>
  <keyword>Ketamine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited between 2009 and 2010 from the ICU.</recruitment_details>
      <pre_assignment_details>All patients who consented were randomized to treatment or placebo.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Normal Saline</title>
          <description>The control group will receive 0.25mg/kg of normal saline over a period of one hour followed by a continuous infusion of normal saline at 0.1 mg/kg/hr for a further 23 hours.</description>
        </group>
        <group group_id="P2">
          <title>Ketamine</title>
          <description>The treatment group will receive 0.25mg/kg of ketamine over a period of one hour followed by a continuous infusion of ketamine at 0.1 mg/kg/hr for a further 23 hours.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Normal Saline</title>
          <description>The control group will receive 0.25mg/kg of normal saline over a period of one hour followed by a continuous infusion of normal saline at 0.1 mg/kg/hr for a further 23 hours.</description>
        </group>
        <group group_id="B2">
          <title>Ketamine</title>
          <description>The treatment group will receive 0.25mg/kg of ketamine over a period of one hour followed by a continuous infusion of ketamine at 0.1 mg/kg/hr for a further 23 hours.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" spread="19"/>
                    <measurement group_id="B2" value="60" spread="11"/>
                    <measurement group_id="B3" value="61" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Serum Levels of IL-6, IL-10 and TNFα</title>
        <time_frame>first 7 days of admission, Baseline and Day 7 reported</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Normal Saline</title>
            <description>The control group will receive 0.25mg/kg of normal saline over a period of one hour followed by a continuous infusion of normal saline at 0.1 mg/kg/hr for a further 23 hours.</description>
          </group>
          <group group_id="O2">
            <title>Ketamine</title>
            <description>The treatment group will receive 0.25mg/kg of ketamine over a period of one hour followed by a continuous infusion of ketamine at 0.1 mg/kg/hr for a further 23 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Levels of IL-6, IL-10 and TNFα</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline IL-10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28" lower_limit="8.1" upper_limit="246.9"/>
                    <measurement group_id="O2" value="16" lower_limit="12.2" upper_limit="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 IL-10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3" lower_limit="4.7" upper_limit="12.9"/>
                    <measurement group_id="O2" value="6.3" lower_limit="5" upper_limit="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline IL-6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3227.7" lower_limit="512" upper_limit="7205.7"/>
                    <measurement group_id="O2" value="613.8" lower_limit="320.8" upper_limit="3190.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 IL-6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="322.8" lower_limit="96.8" upper_limit="428"/>
                    <measurement group_id="O2" value="266.2" lower_limit="56.3" upper_limit="285.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline TNF-alpha</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="1.5" upper_limit="6.2"/>
                    <measurement group_id="O2" value="7.1" lower_limit="3.2" upper_limit="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 TNF-alpha</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="1.2" upper_limit="3.1"/>
                    <measurement group_id="O2" value="6.3" lower_limit="2.4" upper_limit="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Effects Attributable to Ketamine</title>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Normal Saline</title>
            <description>The control group will receive 0.25mg/kg of normal saline over a period of one hour followed by a continuous infusion of normal saline at 0.1 mg/kg/hr for a further 23 hours.</description>
          </group>
          <group group_id="O2">
            <title>Ketamine</title>
            <description>The treatment group will receive 0.25mg/kg of ketamine over a period of one hour followed by a continuous infusion of ketamine at 0.1 mg/kg/hr for a further 23 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Effects Attributable to Ketamine</title>
          <units>adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Organ Failures</title>
        <description>Incidence of new organ failure as detected by Sequential Organ Failure Assessment [SOFA] score. Definitions are as follows. Central nervous system: delirium, coma, uncontrollable seizures, ICP&gt;20cm H2O Cardiac: MAP &lt;60mmHg, blood pressure supported with pressors, 50 &gt; HR &gt; 120 Respiratory: vented, RR&gt;30, PaO2&lt;60, PaCO2 &gt; 55, Sat&lt;92% Kidney: RIFLE criteria Anemia: Hct&lt;27, transfusion of PRBC Thrombocytopenia: platelet &lt; 50k, platelet transfusion Liver: biopsy, ALT&gt;200, AST&gt;200, t.bil&gt;2.0, ALP&gt;300 Coagulation failure: INR&gt;2 if no anticoagulation therapy</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Normal Saline</title>
            <description>The control group will receive 0.25mg/kg of normal saline over a period of one hour followed by a continuous infusion of normal saline at 0.1 mg/kg/hr for a further 23 hours.</description>
          </group>
          <group group_id="O2">
            <title>Ketamine</title>
            <description>The treatment group will receive 0.25mg/kg of ketamine over a period of one hour followed by a continuous infusion of ketamine at 0.1 mg/kg/hr for a further 23 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Organ Failures</title>
          <description>Incidence of new organ failure as detected by Sequential Organ Failure Assessment [SOFA] score. Definitions are as follows. Central nervous system: delirium, coma, uncontrollable seizures, ICP&gt;20cm H2O Cardiac: MAP &lt;60mmHg, blood pressure supported with pressors, 50 &gt; HR &gt; 120 Respiratory: vented, RR&gt;30, PaO2&lt;60, PaCO2 &gt; 55, Sat&lt;92% Kidney: RIFLE criteria Anemia: Hct&lt;27, transfusion of PRBC Thrombocytopenia: platelet &lt; 50k, platelet transfusion Liver: biopsy, ALT&gt;200, AST&gt;200, t.bil&gt;2.0, ALP&gt;300 Coagulation failure: INR&gt;2 if no anticoagulation therapy</description>
          <units>participants with increase in SOFA score</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Physiology and Chronic Health Evaluation (APACHE) Scores</title>
        <description>Difference in average APACHE-II score between the intervention and placebo groups. APACHE II (Acute Physiology and Chronic Health Evaluation II) is a severity of disease classification system for patients admitted to the Intensive Care Unit. It uses an integer score from 0 to 71 that is computed based on age, 12 routine physiological measurements (i.e. heart rate, temperature, laboratory values), and previous health status obtained during the first 24 hours after ICU admission. Higher scores correspond to more severe disease and a higher risk of death.</description>
        <time_frame>First 24 hours after ICU admission</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Normal Saline</title>
            <description>The control group will receive 0.25mg/kg of normal saline over a period of one hour followed by a continuous infusion of normal saline at 0.1 mg/kg/hr for a further 23 hours.</description>
          </group>
          <group group_id="O2">
            <title>Ketamine</title>
            <description>The treatment group will receive 0.25mg/kg of ketamine over a period of one hour followed by a continuous infusion of ketamine at 0.1 mg/kg/hr for a further 23 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Physiology and Chronic Health Evaluation (APACHE) Scores</title>
          <description>Difference in average APACHE-II score between the intervention and placebo groups. APACHE II (Acute Physiology and Chronic Health Evaluation II) is a severity of disease classification system for patients admitted to the Intensive Care Unit. It uses an integer score from 0 to 71 that is computed based on age, 12 routine physiological measurements (i.e. heart rate, temperature, laboratory values), and previous health status obtained during the first 24 hours after ICU admission. Higher scores correspond to more severe disease and a higher risk of death.</description>
          <units>APACHE score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" spread="8"/>
                    <measurement group_id="O2" value="23" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Intensive Care Unit (ICU) Stay</title>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Normal Saline</title>
            <description>The control group will receive 0.25mg/kg of normal saline over a period of one hour followed by a continuous infusion of normal saline at 0.1 mg/kg/hr for a further 23 hours.</description>
          </group>
          <group group_id="O2">
            <title>Ketamine</title>
            <description>The treatment group will receive 0.25mg/kg of ketamine over a period of one hour followed by a continuous infusion of ketamine at 0.1 mg/kg/hr for a further 23 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Intensive Care Unit (ICU) Stay</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" spread="9"/>
                    <measurement group_id="O2" value="20" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>28 Day Mortality</title>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Normal Saline</title>
            <description>The control group will receive 0.25mg/kg of normal saline over a period of one hour followed by a continuous infusion of normal saline at 0.1 mg/kg/hr for a further 23 hours.</description>
          </group>
          <group group_id="O2">
            <title>Ketamine</title>
            <description>The treatment group will receive 0.25mg/kg of ketamine over a period of one hour followed by a continuous infusion of ketamine at 0.1 mg/kg/hr for a further 23 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>28 Day Mortality</title>
          <units>deaths</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>PCR Substudy</title>
        <description>PCR analysis on serum samples for presence of bacterial and mitochondrial DNA; This substudy was not done.</description>
        <time_frame>Daily up to 7 days</time_frame>
        <population>Not done</population>
        <group_list>
          <group group_id="O1">
            <title>Normal Saline Placebo</title>
            <description>The control group will receive 0.25mg/kg of normal saline over a period of one hour followed by a continuous infusion of normal saline at 0.1 mg/kg/hr for a further 23 hours.
Normal Saline placebo: The control group will receive 0.25mg/kg of normal saline over a period of one hour followed by a continuous infusion of normal saline at 0.1 mg/kg/hr for a further 23 hours.</description>
          </group>
          <group group_id="O2">
            <title>Ketamine</title>
            <description>The treatment group will receive 0.25mg/kg of ketamine over a period of one hour followed by a continuous infusion of ketamine at 0.1 mg/kg/hr for a further 23 hours.
Ketamine: The treatment group will receive 0.25mg/kg of ketamine over a period of one hour followed by a continuous infusion of ketamine at 0.1 mg/kg/hr for a further 23 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>PCR Substudy</title>
          <description>PCR analysis on serum samples for presence of bacterial and mitochondrial DNA; This substudy was not done.</description>
          <population>Not done</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Seven days from enrollment.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Normal Saline</title>
          <description>The control group will receive 0.25mg/kg of normal saline over a period of one hour followed by a continuous infusion of normal saline at 0.1 mg/kg/hr for a further 23 hours.</description>
        </group>
        <group group_id="E2">
          <title>Ketamine</title>
          <description>The treatment group will receive 0.25mg/kg of ketamine over a period of one hour followed by a continuous infusion of ketamine at 0.1 mg/kg/hr for a further 23 hours.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <description>Pericardial effusion, possible tamponade. Treated with drainage.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <description>Treated with antiarrythmics</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title vocab="CTCAE">Death</sub_title>
                <description>All deaths in this trial were expected based on patients' clinical course and followed withdrawal of clinical care. None were suspected of being related to trial participation.</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia (atrial fibrillation)</sub_title>
                <description>Clinically expected based on septic presentation. Treated with cardioversion and medication.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Salivation, excessive</sub_title>
                <description>Possibly related</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Daniel Talmor</name_or_title>
      <organization>Beth Israel Deaconess Medical Center</organization>
      <phone>617-754-2675</phone>
      <email>dtalmor@bidmc.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

